

# ForPatients

by Roche

Schizophrenia

## A Trial of the Efficacy and the Safety of RO6889450 vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

**Trial Status**  
Completed

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT04512066 BP41743

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT04512066 BP41743**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years & <= 45 Years

**Healthy Volunteers**  
No

---